Ontology highlight
ABSTRACT:
SUBMITTER: Janku F
PROVIDER: S-EPMC4409143 | biostudies-literature | 2014 Jan
REPOSITORIES: biostudies-literature
Janku Filip F Hong David S DS Fu Siqing S Piha-Paul Sarina A SA Naing Aung A Falchook Gerald S GS Tsimberidou Apostolia M AM Stepanek Vanda M VM Moulder Stacy L SL Lee J Jack JJ Luthra Rajyalakshmi R Zinner Ralph G RG Broaddus Russell R RR Wheler Jennifer J JJ Kurzrock Razelle R
Cell reports 20140116 2
Despite a wealth of preclinical studies, it is unclear whether PIK3CA or phosphatase and tensin homolog (PTEN) gene aberrations are actionable in the clinical setting. Of 1,656 patients with advanced, refractory cancers tested for PIK3CA or PTEN abnormalities, PIK3CA mutations were found in 9% (146/1,589), and PTEN loss and/or mutation was found in 13% (149/1,157). In multicovariable analysis, treatment with a phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) inhibito ...[more]